Clinical Trial Update: Shortened Venetoclax Duration Based on Day 14 BM Blasts Versus Standard Therapy in Elderly or Frail Patients With AML Patients Treated With Azacitidine Plus Venetoclax [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial update evaluating shortening venetoclax duration based on day 14 bone marrow blasts in elderly or frail AML patients treated with azaci…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Venetoclax (Venclexta) (venetoclax)

Snippet

Sponsor: Peking University People's Hospital | Conditions: Acute Myeloid Leukemia | Phase 3 | Status: NOT_YET_RECRUITING